摘要
目的测定胰腺癌肿瘤组织中胸苷磷酸化酶(TP)和二氢嘧啶脱氢酶(DPD)的含量并计算两者的比值,为希罗达在胰腺癌的临床应用提供理论基础。方法选取20例胰腺癌患者,应用ELISA法测定肿瘤组织中TP和DPD的含量,计算两者的比值,并与癌旁正常组织作比较。结果肿瘤组织中TP的含量平均为癌旁正常组织的74倍(5～283倍),两者含量的差异有显著性(P<0.01)。肿瘤组织中DPD的含量也明显升高(P<0.01)。肿瘤组织与癌旁正常组织的TP/DPD比值差异有显著性(P<0.01)。结论胰腺癌中TP/DPD比值较正常胰腺组织明显升高,提示希罗达能在胰腺癌中进行选择性活化,对于治疗胰腺癌应有较高的应用价值。
Objective To determine the contents of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in pancreatic cancer to provide a basis for the clinical use of capecitabine in pancreatic cancer patients. Methods The contents of TP and DPD in pancreatic cancer and adjacent normal tissues from 20 patients were determined by ELISA and the TP to DPD ratios in the cancer and adjacent normal tissue were compared. Results TP content was 5 to 283 fold higher in tumor tissue (mean 74 fold) than in the adjacent normal tissue ( P <0.01). DPD in the cancer tissue increased significantly. So did the TP to DPD ratio, when compared to that in normal pancreatic tissue ( P <0.01). Conclusion The increased TP to DPD ratio in pancreatic cancer suggests that capecitabine could be activated by the cancer, these capable of selectively kill the tumor cells.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2004年第10期618-620,共3页
Chinese Journal of Oncology
